Research Analysts Set Expectations for MLTX Q1 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of MoonLake Immunotherapeutics in a report issued on Thursday, February 27th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.77) per share for the quarter, down from their prior forecast of ($0.69). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.72) EPS and FY2025 earnings at ($3.00) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.09).

Several other equities research analysts have also issued reports on the stock. Needham & Company LLC raised their target price on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group dropped their target price on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Finally, Wedbush reissued an “outperform” rating and set a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $83.20.

MoonLake Immunotherapeutics Stock Performance

NASDAQ:MLTX opened at $40.30 on Monday. The firm has a market capitalization of $2.58 billion, a PE ratio of -31.24 and a beta of 1.28. The stock’s fifty day moving average is $46.24 and its 200 day moving average is $48.89. MoonLake Immunotherapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $58.26.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of MoonLake Immunotherapeutics by 96.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,814 shares of the company’s stock valued at $1,806,000 after acquiring an additional 17,580 shares during the period. Erste Asset Management GmbH purchased a new position in MoonLake Immunotherapeutics in the third quarter valued at about $741,000. Barclays PLC raised its holdings in MoonLake Immunotherapeutics by 1,269.2% in the third quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after purchasing an additional 5,229 shares in the last quarter. State Street Corp grew its position in shares of MoonLake Immunotherapeutics by 96.2% in the 3rd quarter. State Street Corp now owns 87,637 shares of the company’s stock worth $4,419,000 after buying an additional 42,980 shares during the last quarter. Finally, Congress Asset Management Co. raised its stake in shares of MoonLake Immunotherapeutics by 9.5% during the 4th quarter. Congress Asset Management Co. now owns 72,993 shares of the company’s stock worth $3,953,000 after acquiring an additional 6,352 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.